Cancer Survivorship Guidelines

Image

European Journal of Clinical Oncology has announced almost 50 percent discount on article processing charge to commemorate its Anniversary. On behalf of the European journal of clinical oncology, as Editor-in-Chief, it is my distinct honour and privilege to inform you that, we have started the Journal, now we are celebrating the Anniversary and we are privileged to welcome Analytical Society to our European Journal of Clinical Oncology

 Survivorship has become an important aspect of cancer care. With the development of targeted and multi-modality treatments, and more effective treatments generally, prolonged survival or even cure has become commonplace for patients with certain cancers, such as testicular cancer, some lymphomas, breast cancer, colon cancer, and some leukemias, among others.

Survivorship Guidelines:

The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers were developed as a collaborative effort of the Nursing Discipline and the Late Effects Committee. The purpose of these guidelines is to:

  • Provide recommendations for screening and management of late effects that may potentially arise as a result of the treatment for childhood cancer
  • Increase awareness of potential late effects
  • Standardize and enhance follow-up care provided to survivors

These guidelines were developed as a resource for clinicians who provide ongoing healthcare to survivors of pediatric malignancies. They are appropriate for asymptomatic survivors of childhood, adolescent or young adult cancers presenting for routine exposure based medical follow-up. More extensive evaluations are presumed, as clinically indicated, for survivors presenting with signs and symptoms suggesting illness or organ dysfunction.

Scope of the journal:

 It mainly encompasses topics Cancer Biology, prostate cancer, colorectal cancer, cancer Immuno therapy, chemotherapy, cancer radiology, therapeutic cancer, cancer pathology reaching out to analytical scientists worldwide.

Journal accepts original manuscripts in the form of research articles, review articles, Clinical reviews, and commentaries, case reports, perspectives and short communications encompassing all aspects Clinical Oncology related topics for publication in open access platform. All the manuscript published are available freely online immediately after publication without any subscription charges or registration. Those who are interested to submit the editorials or their commentaries can submit at https://www.scholarscentral.org/submissions/european-clinical-oncology.html or you can mail  through this mail id as  an attachments  clinoncol@peerjournal.org/oncology@peerjournal.org .

How we work: After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days. A 21-day window time frame is allotted for peer-review process wherein multiple experts are contacted. Author proof is generated within 7 working days after the acceptance decision

Benefits on Publication: Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership. Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Regards

Alfreda Johnson
Managing Editor
European Journal of Clinical Oncology.
WhatsApp: +1504-608-2390
E-mail id: oncology@peerjournal.org